Cel-sci Corp (NYSEMKT:CVM)

CAPS Rating: 1 out of 5

The Company engages in the research and development of drugs and vaccines. Its most advanced product, Multikine, manufactured using the Company's proprietary cell culture technologies, is being developed for the treatment of cancer.

Results 1 - 20 of 21 : 1 2 Next »

Recs

1
Member Avatar asilverp (56.60) Submitted: 8/28/2014 12:28:41 PM : Underperform Start Price: $1.06 CVM Score: +49.39

Stats are terrible. At least 50% downside imho.

Recs

1
Member Avatar ejad1 (< 20) Submitted: 1/15/2014 7:40:36 PM : Outperform Start Price: $0.97 CVM Score: -53.32

CVM is expecting to conclude its phase III of Multikrine end 2014 or early 2015

Recs

2
Member Avatar jressle (< 20) Submitted: 12/31/2010 1:19:29 AM : Outperform Start Price: $8.40 CVM Score: -154.26

cancer, cured

Recs

2
Member Avatar maniacdog10 (50.51) Submitted: 12/21/2010 5:17:15 PM : Outperform Start Price: $8.25 CVM Score: -154.32

I really beleive they will make it

Recs

0
Member Avatar unitedncf (< 20) Submitted: 9/23/2010 1:43:16 AM : Outperform Start Price: $7.44 CVM Score: -172.06

Traded this stock for 9 years. Follow the charts. Any gap up will be filled. Any day it goes up 11% or more...sell it all.

Recs

3
Member Avatar mrnash33 (< 20) Submitted: 8/16/2010 10:04:23 AM : Outperform Start Price: $5.10 CVM Score: -175.85

While a few of these bloggers out there have shorted the stock and talked it down, the fact is the company does have a product. It has taken them time to get to market because they do not have the budgets that the big Pharma companies have, but they do have a proven product. Most of the nay-sayers have shorted the stock, not because it is bad, but because it is so cheap and easy to manipulate - don't fall for that - look at the facts. Buy while it is cheap - what can it hurt and it very well might make you some big money.

Recs

1
Member Avatar ChefDna (< 20) Submitted: 8/4/2010 3:59:00 PM : Outperform Start Price: $5.35 CVM Score: -168.44

The stars are finally lined up for Cel-Sci! When phase 3 trials show what Multikine is capable of, the orders, and CASH will POUR in.

Recs

5
Member Avatar DarthMaul09 (29.89) Submitted: 10/16/2009 12:58:56 AM : Underperform Start Price: $15.50 CVM Score: +181.95

Purely speculative bet that the 25% increase in stock price today was a bit excessive, although it was no were near the pop in had in August. I'm just a little pessimistic that the company can deliver a product worthy of the stock gain.

Recs

1
Member Avatar Coke786 (74.14) Submitted: 9/30/2009 1:26:36 PM : Outperform Start Price: $17.00 CVM Score: -187.22

Dedicated management team who have stuck with the company in its worst times indicates that the management team has full confidence in their product.

Recs

1
Member Avatar lookinfora10bag (< 20) Submitted: 9/28/2009 4:58:29 PM : Outperform Start Price: $18.00 CVM Score: -186.43

Biomed far ahead of competition in many ways. Large investor(s) just put in $20M. FDA in full cooperation with company and looking for fast tracking.

Recs

1
Member Avatar accute (< 20) Submitted: 9/28/2009 3:03:51 PM : Outperform Start Price: $17.71 CVM Score: -186.88

This has been a long time coming; everything is lining up and this thing should rock, once they are granted Phase III, facility certification, and EUA.

Recs

1
Member Avatar ls27 (< 20) Submitted: 9/28/2009 2:37:12 PM : Outperform Start Price: $17.50 CVM Score: -186.84

CVM has a treatment for swine flu. Its LEAPS vaccines identify a virus and stimulate the immune system to pruduce the specific reponse needed to combat that particular microbe. The potential for profits is huge!

Recs

0
Member Avatar dumflick (< 20) Submitted: 9/26/2009 11:19:35 AM : Outperform Start Price: $17.70 CVM Score: -189.38

h1n1, nuff said.

Recs

1
Member Avatar throback (< 20) Submitted: 9/23/2009 9:09:49 AM : Outperform Start Price: $18.70 CVM Score: -185.11

Biomedreport Article:"Scientists at Cel-Sci Corporation, a publicly traded company based in Vienna, VA, have come up with a novel approach that causes an immune response from the body unlike any of the ones previously developed by pharmaceutical companies and vaccine makers. The treatment received the attention of government officials in the U.S. and the FDA gave the group an unusually swift approval to conduct clinical trials of its drug candidate. The company has begun testing its effect on white blood cells of patients who are hospitalized. Given the fact that there are no other treatments for H1N1 and that this is an unmet medical need, experts in biotechnology believe that the company could also be set for a faster approval as well.

The company developed the heteroconjugate technology referred to as LEAPS (Ligand Epitope Antigen Presentation System), which is intended to selectively stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune, allergies, transplantation rejection and cancer, when it cannot do so on its own.

Details about the workings of the drug have been hard to find, but medical experts say that the fact that the treatment has caught the attention of the FDA and CDC, speaks volumes about it's efficacy."

Recs

0
Member Avatar tinsations (< 20) Submitted: 9/22/2009 5:55:33 PM : Outperform Start Price: $18.70 CVM Score: -185.11

H1N1 scare is real. FDA does not back a pump and dump. CVM has FDA backing for trial of NEW approach at treating H1N1 patients. This is not a vaccine!!! A new plant to come on line in weeks not months. Plus phase three trial that is now funded. I say a buy @ below 2.00 and have loaded my ship at below 1.00 a couple weeks ago - holding for a 3x and more this year.

Recs

0
Member Avatar beawinner2 (< 20) Submitted: 9/22/2009 4:11:21 PM : Outperform Start Price: $18.70 CVM Score: -185.11

I've owned it and traded it since it was .21

I'm happy.

Recs

0
Member Avatar dorstop (< 20) Submitted: 9/22/2009 3:42:04 PM : Outperform Start Price: $18.80 CVM Score: -185.49

Drug trials take time and money - lots of both!

Recs

4
Member Avatar topconductor1 (< 20) Submitted: 9/21/2009 2:43:11 PM : Outperform Start Price: $18.90 CVM Score: -186.64

The fundamentals:

The focus of Cel Sci on the enhancement and modification of cell-mediated immunity represents a fundamentally interesting approach in medicine. The “flagship” product is Multikine for the treatment of head and neck cancer. Regulatory progress is now reached the point of having obtained FDA approval for phase 3 study. If positive the planned phase 3 trial would likely be a pivotal trial. The endpoints and subject numbers involved provide seem reasonable and obtainable. The lack of serious adverse events suggests a favorable weighting of risk in evaluating the risk benefit calculus for the drug. If proven effective in the target indication of head and neck cancer, Multikine might be investigated for clinical effects in other types of cancer, and if these studies proved positive, this would represent a further expansion in the potential market.

Very recently the company has received attention regarding its effort to develop an approach to the acute care of HN1. The FDA has been receptive and there is reportedly and evidently a positive, collaborative relationship of the FDA and the company. I believe that this may bode well for the future phase 3 trial work with Multikine. The company has been able to raise reasonable expectable level of funding for the Multikine phase 3 clinical trial.

Technical aspects: Of interest with regard to the chart are:

1.) Very heavy, and largely unprecedented volume in the last two weeks with as much as 60 million shares, the equivalent of over 40% of the entire market cap of all shares trading in a single day. There appear to be consistent levels of support/resistance overthe stock’s existence since it began in 1991. There is recent, impressive upward movement through resistance levels, including gapping with confirmation and consolidation, and putatively bullish formations such as head and shoulders.

Disclaimer: I own shares. My interest in the stock is mainly based on my evaluation of the scientific and clinical significance of the enhancement and modification of cell-mediated immunity. which I accumulated from 25 cents to six dollars starting in 1996. It is my biggest position.

Recs

2
Member Avatar striper56 (76.59) Submitted: 9/20/2009 5:39:31 PM : Outperform Start Price: $16.90 CVM Score: -187.34

10 bagger here if h1n1 vaccine makes it thru the pipeline

Recs

1
Member Avatar awallejr (77.23) Submitted: 9/18/2009 4:45:40 PM : Outperform Start Price: $16.90 CVM Score: -187.34

Bought this at .49, sold off some to recoup costs, and sitting on free stocks thanks to listening to Becon's thread awhile back. I still like the long term potential on this, not because of the h1n1 play, but its multikine play. Here's an interesting video. Of course the CEO might be overly exuberant, but then again

http://www.cel-sci.com/video4REVIEW.html

Results 1 - 20 of 21 : 1 2 Next »

Featured Broker Partners


Advertisement